Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Core US Aggregate Bond ETF (AGG) vs Dolby Laboratories, Inc. (DLB) Price & Performance

iShares Core US Aggregate Bond ETF
Dolby Laboratories, Inc.

Price performance

Price movement over the last 24 hours

Key statistics

iShares Core US Aggregate Bond ETF vs Dolby Laboratories, Inc. — how do they compare? iShares Core US Aggregate Bond ETF trades at $98.06, while Dolby Laboratories, Inc. trades at $50.35 (market cap $4.66B). The key difference: Dolby Laboratories, Inc. pays a 2.86% dividend while iShares Core US Aggregate Bond ETF pays none. Which is the better fit depends on your goals.

AGGDLB
Sector
Fixed IncomeIndustrials
52-Week High
$101.40$76.79
52-Week Low
$97.63$49.31
Market Cap
$4.66B
Enterprise Value
$4.12B
Dividend Yield
2.86%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Core US Aggregate Bond ETF

AGG trades at $98.65, up 0.04% on the day, with technical indicators showing a bearish trend from moving averages but a neutral signal from oscillators. The stock faces resistance at $99 and support at $98. Recent corporate actions include scheduled dividends for May and June 2026. Financial ratios are unavailable in the provided data, limiting fundamental analysis.

The outlook remains cautious due to the bearish technical bias and lack of current financial metrics. Key risks include market volatility and interest rate uncertainty. Investors should await updated earnings reports for a clearer fundamental picture before considering positions.

Dolby Laboratories, Inc.

DLB trades at $49.31, down 3.6% today, with technical indicators showing bearish momentum. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.37 versus $1.31 expected. Revenue remains stable at $1.35B for 2025, with robust gross margins of 87.44%. Recent developments include FDA progress for zervimesine in DLB psychosis and recognition as GM's 2025 Supplier of the Year.

Despite near-term technical weakness, DLB's patent-protected revenue streams and high profitability support long-term value. The consensus price target of $87.50 implies significant upside, but investors face risks from cyclical end-markets and potential dilution from drug development. The stock presents a contrarian opportunity with 47% analyst buy ratings amid current bearish sentiment.

Returns comparison

Trailing returns across standard periods

About iShares Core US Aggregate Bond ETF

AGG tracks the Bloomberg U.S. Aggregate Bond Index, providing broad exposure to the total U.S. investment-grade bond market. It serves as a core portfolio building block by diversifying across Treasuries, government-related bonds, corporate debt, and mortgage-backed securities.

Read more on AGG

About Dolby Laboratories, Inc.

Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.

Read more on DLB